TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04095858
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
Study: NCT04702074
Drug: Traditional Chinese medicine granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months.
Study: NCT04702074
Drug: Traditional Chinese medicine granules placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules .
Study: NCT05450289
Drug: Nigella Sativa Oil
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
Study: NCT05450289
Drug: Standard pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
Study: NCT06663995
Drug: Study Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy
Study: NCT06663995
Drug: Control (placebo) group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).
Study: NCT05036083
Drug: Iodinated Contrast Agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05394298
Drug: Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
Study: NCT06131918
Drug: Super Oxide Dismutase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Study: NCT06583083
Drug: P-GEMOX Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
Study: NCT01969656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06672185
Drug: ARC101
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARC101 will be administered according to an assigned dose schedule.
Study: NCT06672146
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04972760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 mg/d, oral route for 24 weeks
Study: NCT05779163
Drug: LBL-033 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose - MTD; Q2W; intravenous infusion
Study: NCT06671041
Drug: Preservative Free eye drop
Normalized name: GenTeal Tears Moderate Lubricant Preservative Free Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were required to use a lubricating eye drop
Study: NCT05668741
Drug: VX-522 mRNA therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral inhalation using nebulizer.
Study: NCT05658380
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
Study: NCT05363917
Drug: Natrunix with MTX placebo (+folate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
Study: NCT05363917
Drug: Natrunix placebo with MTX (+folate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natrunix placebo with MTX (+folate)
Study: NCT04828824
Drug: Ethinyl Estradiol / Norgestimate Oral Tablet
Normalized name: ethinyl estradiol / norgestimate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
Study: NCT06672445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active treatment by IT administration
Study: NCT06616194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral disintegrating tablets
Study: NCT05334329
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06801015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by subcutaneous injection once per week.
Study: NCT05475678
Drug: TCb regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel + carboplatin regimen
Study: NCT06172894
Drug: APN401
Approvals — FDA: no, EMA: no, PMDA: no
Description: APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
Study: NCT06468371
Drug: Dopamine Agonist (Ropinirole)
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
Study: NCT06608992
Drug: SURGICEL® Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
Study: NCT06388824
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
Study: NCT03561376
Drug: Topical zinc oxide vs. petrolatum post-surgical scars
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following linear closure on non-scalp skin with scar length \> 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery.
Study: NCT04724928
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
Study: NCT06674486
Drug: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France).
Study: NCT06674486
Drug: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
Study: NCT06657300
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
Study: NCT05740007
Drug: IW-3300 rectal foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-3300 rectal foam administered daily for 12 weeks
Study: NCT05740007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rectal foam administered daily for 12 weeks
Study: NCT05440656
Drug: Cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Severe Eosinophilic Asthma
Study: NCT05890105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
Study: NCT05126238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
Study: NCT06479603
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
Study: NCT05073692
Drug: SU
Normalized name: SUMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to the class of drugs known as Sulfonylureas (SU)
Study: NCT05073692
Drug: SGLT2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Study: NCT05073692
Drug: SU or DPP4 (excluding saxagliptin and alogliptin)
Normalized name: SUS SCROFA EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
Study: NCT04561180
Drug: EG-009A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an Intramuscular injection
Study: NCT04561180
Drug: EG-009A Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an Intramuscular injection
Study: NCT05134857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
Study: NCT06084806
Drug: [18F]F-ARAG PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two imaging sessions
Study: NCT06543992
Drug: Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
Study: NCT05109312
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT05109312
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg
Study: NCT05109312
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g
Study: NCT06494878
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin injections daily as prescribed by the treating physician.
Study: NCT06746753
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomized to receive Norepinephrine continuous infusion for up to 48 hours
Study: NCT06747247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appear similar to MT1013, but has no treatment effect.
Study: NCT06607029
Drug: the opioid-based control group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
Study: NCT05383820
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
Study: NCT05127486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05127486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05988814
Drug: FOLFIRINOX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression
Study: NCT05402384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05932732
Drug: ReGen-GF
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
Study: NCT06301854
Drug: TPN171H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
Study: NCT05113940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days
Study: NCT05789992
Drug: Low Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Random:0-3ug/ml)
Study: NCT05789992
Drug: Heigh Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Random:3-5ug/ml)
Study: NCT04147949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules taken twice a day for 14 days
Study: NCT05705726
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
Study: NCT05510986
Drug: Fentanyl group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
Study: NCT05229965
Drug: Paracetamol Codeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
Study: NCT04751500
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving medications to contract the womb to pass the retained pregnancy tissue
Study: NCT05079438
Drug: Dendrobium Huoshanense Suppository
Normalized name: Dendrobium moniliforme whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7g rectal administration per day for 5 weeks
Study: NCT05899725
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
Study: NCT05593432
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study: NCT06327152
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants randomized to receive caffeine will continue to receive caffeine at the current weight-based dose (which is the standard of care maintenance dose of 10-15 mg/kg/day) given every 24 hours. The weight-based dose calculated using the weight at the time of enrollment will be the weight-based dose used for the duration of the study. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.~The study drug (caffeine) will be administered for a maximum of 4 weeks. The study drug will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The study drug will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications.
Study: NCT04990739
Drug: MTB-9655
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime.
Study: NCT06090474
Drug: NDC-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NDC-002B and NDC-002C
Study: NCT05771428
Drug: Placebo for ABBV-552
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06004661
Drug: AAA617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously once every cycles (1 cycle = 6 weeks)
Study: NCT04714372
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
Study: NCT06098014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare with Thalidomide
Study: NCT05698186
Drug: Thero2-01S22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Study: NCT05698186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Study: NCT05698186
Drug: Thero2-01S22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Study: NCT05459597
Drug: antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
Study: NCT05819229
Drug: Oral antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days.
Study: NCT00002103
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05966818
Drug: Standard Therapy (ACEI or ARB).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy which include either ACEI or ARB for 24 weeks.
Study: NCT00226642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no